BURL Concepts

Executive Summary

BURL Concepts is a San Francisco-based medical device startup founded in 2020, focused on revolutionizing stroke diagnosis and neurological trauma management through its proprietary SONAS® technology. The company aims to address the critical gap in rapid, affordable cerebral blood flow assessment, which is essential for improving patient outcomes in stroke and other neurological conditions. By providing a non-invasive, inexpensive, and state-of-the-art test, BURL Concepts targets both hospital and non-hospital settings, potentially enabling earlier intervention and reducing the devastating effects of stroke. The company operates at the intersection of drug delivery and medical devices, with a clear mission to maximize clinical outcomes through accessible diagnostic tools. While still in a private stage with no disclosed funding or valuation, BURL Concepts is positioned to capitalize on the growing demand for point-of-care neurological diagnostics and the increasing emphasis on early stroke detection. The technology's non-invasive nature and rapid turnaround time could differentiate it from existing imaging modalities like CT or MRI, which are costly, time-consuming, and less accessible in pre-hospital or resource-limited environments. As the company progresses, successful validation and commercialization of SONAS® could establish BURL Concepts as a key player in the stroke diagnostics market, which is expected to grow significantly due to aging populations and rising stroke incidence.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical trial for SONAS®60% success
• Q2 2027FDA 510(k) clearance or De Novo classification50% success
• TBDStrategic partnership with a major hospital network or stroke center70% success